Caxton Corporation’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-3,896
| Closed | -$880K | – | 19 |
|
|
2022
Q3 | $880K | Hold |
3,896
| – | – | 1.65% | 10 |
|
|
2022
Q2 | $736K | Hold |
3,896
| – | – | 0.99% | 10 |
|
|
2022
Q1 | $970K | Hold |
3,896
| – | – | 1.21% | 13 |
|
|
2021
Q4 | $607K | Sell |
3,896
-791
| -17% | -$123K | 0.5% | 38 |
|
|
2021
Q3 | $939K | Buy |
4,687
+66
| +1% | +$13.2K | 0.76% | 18 |
|
|
2021
Q2 | $1.18M | Buy |
4,621
+1,485
| +47% | +$380K | 0.81% | 15 |
|
|
2021
Q1 | $833K | Buy |
3,136
+501
| +19% | +$133K | 0.54% | 18 |
|
|
2020
Q4 | $972K | Sell |
2,635
-1,127
| -30% | -$416K | 0.61% | 16 |
|
|
2020
Q3 | $919K | Buy |
3,762
+1,029
| +38% | +$251K | 0.87% | 12 |
|
|
2020
Q2 | $787K | Buy |
2,733
+12
| +0.4% | +$3.46K | 0.83% | 11 |
|
|
2020
Q1 | $555K | Buy |
2,721
+651
| +31% | +$133K | 0.61% | 11 |
|
|
2019
Q4 | $925K | Buy |
2,070
+3
| +0.1% | +$1.34K | 0.89% | 11 |
|
|
2019
Q3 | $636K | Buy |
2,067
+4
| +0.2% | +$1.23K | 0.72% | 12 |
|
|
2019
Q2 | $656K | Buy |
2,063
+420
| +26% | +$134K | 0.75% | 12 |
|
|
2019
Q1 | $689K | Buy |
1,643
+186
| +13% | +$78K | 0.64% | 13 |
|
|
2018
Q4 | $444K | Buy |
1,457
+607
| +71% | +$185K | 0.54% | 15 |
|
|
2018
Q3 | $306K | Buy |
+850
| New | +$306K | 0.28% | 20 |
|